Both neutralizing and nonneutralizing immunoglobulin G2a monoclonal antibodies (MAs) directed against the E2 glycoprotein of Semliki Forest virus (SFV) protected mice prophylactically and therapeutically against virulent SFV infection. The neutralizing MAs, however, conferred protection to mice at lower doses than did nonneutralizing MAs. The antibody-dependent, complement-mediated cytolysis of SFV-infected L cells was effectuated by both kinds of antibodies, but again neutralizing MAs were more effective. Removal of the Fc part of the neutralizing MA UM 5.1 by pepsin digestion resulted in a 100-fold reduction of the neutralization titer (104 versus 106) and a complete loss of its capacity to mediate antibody-dependent, complement-mediated cytolysis. Passive protection of infected mice occurred only after administration of relatively high doses of F(ab')2 of MA UM 5.1 (30.0 ,ug versus 0.1 ,ug). F(ab')2 fragments prepared from the nonneutralizing MA UM 4.2 had lost their protective capacity completely. Surprisingly, the nonneutralizing MA UM 4.2 retarded virus growth in mouse fibroblasts (L cells), although inhibition was at much higher doses than with the neutralizing MA UM 5.1. Furthermore, both MAs promoted the uptake of virulent SFV in the Fc receptor-bearing WEHI-3 cells. The results suggest that nonneutralizing MAs protect mice not only by antibody-dependent, complement-mediated cytolysis but also by growth inhibition and enhanced uptake of SFV in the nonpermissive macrophages of BALB/c mice. This hypothesis is supported by the absence of viremia in recipients of nonneutralizing MA UM 4.2 at 24 h after infection.
Previous studies have indicated that both neutralizing and nonneutralizing monoclonal antibodies (MAs) directed against either the E1 or E2 glycoprotein of Semliki Forest virus (SFV) protect mice passively against an otherwise lethal infection with virulent SFV (1, 2) . Nonneutralizing MAs could be subclassified as protective and nonprotective MAs. The protective capacity of MAs is presumably related to the epitope recognized and the immunoglobulin subclass (2, 7, 17, 18) . In earlier studies, mice were infected 2 h after the intravenous transfer of MAs. In the present study, we demonstrate that both neutralizing and nonneutralizing MAs can be successfully used for long-term prophylaxis and short-term therapy. This study investigates the mechanism(s) by which nonneutralizing MAs could prevent lethal encephalitis caused by virulent SFV in mice. One of the mechanisms by which nonneutralizing MAs may provide protection is antibody-dependent, complement-mediated cytolysis (ADCMC) which already has been suggested for the closely related Sindbis virus (21) . We also considered and investigated other possible mechanisms for these nonneutralizing MAs, including in vivo neutralization, retardation of virus replication by blocking of virus receptors, and MA-mediated uptake of SFV in nonpermissive macrophages.
In this study, the biological functions of E2-specific MAs of the immunoglobulin G2a (IgG2a) immunoglobulin subclass and their F(ab')2 fragments were compared.
MATERIALS AND METHODS
Virus strains. The virulent strain SF/LS 10 Cl/A was received from C. J. Bradish (3) and passed twice through BALB/c mice. Brain suspensions of the second passage were pooled, divided in small portions, and kept in ampoules above liquid nitrogen. The repeated plaque titration ofthawed * Corresponding author.
brain material resulted in virus titers of 6 x 105 PFU/ml. Brain suspensions containing virulent SFV were used for plaque reduction tests and infection of mice. The intraperitoneal (i.p.) 50% lethal dose (LD50) for male BALB/c mice was 1 to 2 PFU of the virulent strain. The avirulent SFV strain MRS MP 192/7 was obtained from K. G. Oei (Royal Tropical Institute of Amsterdam, Amsterdam, The Netherlands). The general virological methods have been described previously (2, 14) .
Cells and media. L cells, a continuous line of mouse fibroblasts grown in Dulbecco minimal essential medium with 0.01 M N-2-hydroxyethylpiperazine-N'-ethanesulfonic acid supplemented with 5% calf serum and antibiotics, were used throughout this study. The complete growth medium was also used for diluting infectious virus or cells to the required concentrations. The same medium was used for WEHI-3 cells, which have characteristics of macrophages (23) .
Animals. Inbred BALB/c mice were bred and maintained in our own animal house. Male mice of ca. 12 weeks of age were used for protection experiments against i.p. infection with virulent SFV.
Monoclonal antibodies. The production, purification, and biological characterization of the IgG2a MAs directed against the E2 glycoprotein of SFV are described in other papers (1, 2) .
Preparation of F(ab')2 fragments. F(ab')2 fragments of MAs UM 4.2 and UM 5.1 were prepared by pepsin digestion. The optimal conditions for pepsin digestion were determined by titrating the pepsin ( (2) . b The highest dilutions of purified monoclonal antibodies (1 mg/ml) causing 50% plaque reduction with virulent SFV. ' The test was performed with a 1:50 dilution (80 jig per well) of purified MAs. Less than 5% lysis was measured in controls of infected cells with MAs and inactivated complement. horseradish peroxidase-conjugated (1:5,000 dilution) E1-specific MAs (UM 8.47 and UM 8.64) (22) . After incubation for 1 h at 37°C, the plates were washed three times with PBS and shaken dry. The amount of bound enzyme was visualized by incubating the wells with 0.05 ml of substrate solution containing 3',3',5',5'-tetramethylbenzidine (Sigma) and urea peroxide (Organon Teknika, Boxtel, The Netherlands) (22) . After 30 min of incubation at room temperature, the enzyme reaction was stopped with 0.05 ml of 1 Another factor which may confer protection is formation of antiidiotypic antibodies (20) .
On an equal weight base, the neutralizing MAs were more effective in protection than nonneutralizing MAs. Moreover, the protective dose of purified neutralizing MAs was clearly inversely related to their neutralization titer. The mechanism of virus neutralization is still not completely understood (6) . Hitherto one could only speculate on the mechanism by which nonneutralizing MAs afford protection. For virulent alphaviruses, ADCMC of infected cells is proposed (21) . Early lysis of infected cells leads to reduced production of virulent virus, which allows the animal to build up its own effective immune response before irreversible damage has been inflicted. Surprisingly, the effectiveness of the MAs in the ADCMC test was correlated to their neutralization titer. (23) .
The role of the Fc part of MAs in protective immunity is further exemplified in experiments in which this part was removed by pepsin digestion. F(ab')2 fragments of the nonneutralizing MA UM 4.2 lost their protective capacity in vivo completely, whereas at least a 100-fold reduction was observed for F(ab')2 fragments obtained from the neutralizing MA UM 5.1. This loss in effectiveness of biological functions might be due to reduced uptake by macrophages and the absence of a mechanism in vivo which is similar to ADCMC. Moreover, F(ab')2 fragments of the neutralizing MA UM 5.1 were, on an equal basis, 100-fold less effective in neutralization (104 to 106) compared with parent molecules. We speculate that these F(ab')2 fragments are less able to deform virus particles which is assumed to play a role in neutralization (5, 6, 16 
